Key Takeaways
- FUJIFILM Cellular Dynamics, Inc. has opened a new headquarters and facility in Madison, expanding its manufacturing capacity fourfold.
- The new site will increase production of iPSC-derived iCell products, used in drug discovery and development.
- The facility is designed to be scalable for contract manufacturing of cell therapy products, from investigational to commercial production.
- The $200 million investment by Fujifilm will integrate state-of-the-art capabilities in the 175,000-square-foot building.
- The use of iPS cell-derived differentiated cells is becoming increasingly popular in drug development due to regulatory guidance and their ability to accurately reproduce human biological functions.
Introduction to FUJIFILM Cellular Dynamics' New Facility
FUJIFILM Cellular Dynamics, Inc. has officially opened its new headquarters and facility in Madison, marking a significant expansion of its manufacturing capacity. The new site is expected to quadruple the company's production of iPSC-based research products and services, including its iCell product lines. These products are increasingly being used in new approach methods (NAMs) for drug discovery, which have gained popularity in recent years due to regulatory guidance in the United States and Europe.
Expansion of Manufacturing Capabilities
The new facility will enable FUJIFILM Cellular Dynamics to expand its manufacturing capabilities, including the production of iCell products. These products are derived from induced pluripotent stem cells (iPSCs) and are used to evaluate the efficacy and safety of new drugs at the preclinical stage. The use of iPS cell-derived differentiated cells has become increasingly popular in drug development due to their ability to accurately reproduce human biological functions.
Comparison of Traditional and NAM Methods
| Method | Description | Advantages |
|---|---|---|
| Traditional Animal Testing | Uses animals to test the efficacy and safety of new drugs | Well-established, widely accepted |
| New Approach Methods (NAMs) | Uses alternative methods, such as iPS cell-derived differentiated cells, to test the efficacy and safety of new drugs | More accurate, humane, and cost-effective |
Facility Specifications and Investment
The new facility is a 175,000-square-foot building that integrates state-of-the-art capabilities. The $200 million investment by Fujifilm is part of a strategic plan to expand the company's capabilities in the life sciences sector. The facility is designed to be scalable, accommodating a wide range of processes, from investigational drug manufacturing to commercial production.
Bottom Line
The opening of FUJIFILM Cellular Dynamics' new facility in Madison marks a significant milestone in the company's expansion plans. With its increased manufacturing capacity and state-of-the-art capabilities, the company is well-positioned to meet the growing demand for iPSC-derived products and services in the life sciences sector. As the industry continues to shift towards NAMs, FUJIFILM Cellular Dynamics is poised to play a leading role in the development and manufacture of these innovative products.